Compare CLWT & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | ENVB |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 8.1M |
| IPO Year | 1996 | 2000 |
| Metric | CLWT | ENVB |
|---|---|---|
| Price | $1.23 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 389.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $0.56 |
| 52 Week High | $1.63 | $13.25 |
| Indicator | CLWT | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 54.23 | 40.63 |
| Support Level | $1.13 | $1.83 |
| Resistance Level | $1.31 | $4.29 |
| Average True Range (ATR) | 0.06 | 0.23 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 45.68 | 29.55 |
Euro Tech Holdings Co Ltd is a distributor and manufacturer of technology instruments as well as an environmental engineering services provider. It is engaged in the marketing and trading of water and wastewater related process control, analytical and testing instruments, disinfection equipment, supplies, and related automation systems. There are two operating segments of the company. The Trading and manufacturing segment, which is the key revenue driver, includes distribution of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies and power generation equipment. The Engineering segment includes water and waste-water treatment engineering and air pollution control business. The majority of the revenue is generated from Hong Kong.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.